Screener / SEC EDGAR /CIK 0000882796 /10-K filed Feb 26, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Biotechnology

Biocryst Pharmaceuticals Inc BCRX

We are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by our deep commitment to improving the lives of people living with these conditions. 10-K, Item 1

Headquarters
Durham, NC
Next results
around Jan 11, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $874.8M through the costs to a net profit of $263.9M · income statement of the 10-K

39% operating margin
Revenue to Gross profit: $855.8MRevenue to Cost of revenue: $19.1MGross profit to Operating profit: $341.0MGross profit to Operating expenses: $514.8MOperating profit to Net profit: $263.9MOperating profit to Tax & other: $77.1MOperating expenses to R&D: $166.1MOperating expenses to SG&A: $348.6M Revenue: $874.8M REVENUE $874.8M +94% Y/Y Gross profit: $855.8M · 98% margin GROSS PROFIT $855.8M 98% margin Cost of revenue: $19.1M · 2% of revenue COST OF REVENUE $19.1M 2% of revenue Operating profit: $341.0M · 39% margin OPERATING PROFIT $341.0M 39% margin Operating expenses: $514.8M · 59% of revenue OPERATING EXPENSES $514.8M 59% of revenue Net profit: $263.9M · 30% margin NET PROFIT $263.9M 30% margin Tax & other: $77.1M · 9% of revenue TAX & OTHER $77.1M 9% of revenue R&D: $166.1M · 19% of revenue R&D $166.1M 19% of revenue SG&A: $348.6M · 40% of revenue SG&A $348.6M 40% of revenue
Gross profit $855.8M 98% margin
Operating profit $341.0M 39% margin
Net profit $263.9M 30% margin
The full income statement, year by year

BCRX among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 94.1%, above 95% of 154 peers (their median 10.4%) REVENUE GROWTH 94.1% · above 95% Gross margin: 97.8%, above 100% of 107 peers (their median 63.4%) GROSS MARGIN 97.8% · above 100% Operating margin: -30.1%, above 15% of 138 peers (their median 10.2%) OPERATING MARGIN -30.1% · above 15% Net margin: -37.4%, above 13% of 153 peers (their median 6.8%) NET MARGIN -37.4% · above 13% FCF margin: 38.0%, above 97% of 144 peers (their median 9.9%) FCF MARGIN 38.0% · above 97%
BCRX Peer median Below the median

What changed

30 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 26, 2026 against Feb 25, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Critical audit matters changed
    New this year: Divestiture of BioCryst Ireland Limited (“As described in Note 2 to the consolidated financial statements, the Company sold to Neopharmed Gentili S.p.A (“Neopharmed”) all of its equity interests in BioCryst Ireland, and amended and restated their existing intellectual property license agreement. In connection with the transaction, the Compa”). No longer listed: Table of Contents; Royalty Financing Obligations
  • Receivables +35.1% ($79.1M to $106.8M) vs revenue +94.1% ($450.7M to $874.8M), -59.0 pts apart
9 more checks with nothing to note
  • Cash from operations $347.4M vs net income $263.9M (FY ending Dec 31, 2025)
  • Inventory -33.3% ($8.1M to $5.4M) vs revenue +94.1% ($450.7M to $874.8M), -127.4 pts apart
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

30 paragraphs in Risk Factors that were not in the 10-K filed Feb 25, 2025. Quoted as filed.

All 30 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    If the benefits of the Merger do not meet the expectations of investors or securities analysts, the market price of our common stock may decline. The market price of our common stock may decline as a result of the Merger if we do not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    In addition, we do not know if, when, or how the FDA, Congress, or future judicial challenges may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    We may face competition from biosimilars, which may have a material adverse impact on the future commercial prospects of our biological products and product candidates. Even if we are successful in achieving regulatory approval to commercialize a biological product candidate faster than our competitors, we may face competition from…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    The process of manufacturing pharmaceutical products, devices and, in particular, biologics, is complex, highly regulated, and subject to multiple risks. Manufacturing biologics is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error,…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$270.8M$331.4M$450.7M$874.8M
Net income−$247.1M−$226.5M−$88.9M$263.9M
Operating cash flow−$161.8M−$95.1M−$52.0M$347.4M
Free cash flow−$163.2M−$97.3M−$53.1M$344.9M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$874.8M ▲ 94.1% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

2 filings in the last 30 days · SEC EDGAR

All filings

About the company

Biocryst Pharmaceuticals Inc, Durham, NC · from the 10-K filed Feb 26, 2026

We are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by our deep commitment to improving the lives of people living with these conditions. We have built a robust commercial infrastructure to support the successful commercialization of ORLADEYO, an oral, once-daily therapy discovered and developed internally for the prevention of HAE attacks.

Headquarters
Durham, NC
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 4, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 25, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BCRX/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.